

Prof. Hazem Khamis

Professor & Head of Cardiology Department - MTI University
and National Heart Institute and Geriatric Hospital
of Med. elfeel Hospital - National Defense Authority

Prof. Hazem Khamis is a Professor and Consultant Clinical Cardiologist, Member of Board Directors (Egyptian NHDO), Vice Dean Faculty of medicine MTI and Professor of cardiology in MTI. He is a Consultus in Cardiology & Heart Health Implementations in Egypt for Example health insurance and Universal health insurance Authority.

He has a great experience in field of health and healthcare organization after graduation from Faculty of medicine then joining Armed forces sector and develop in positions and skills till reach management and influence and strategy healthcare environment in Egypt and Cardiology field in specialty.

Prof. **Hazem Khamis** Has many attributes in Cardiology field as being the first operator in Egypt to do Renal denervation, Mitra clip, Occlusion device and AVG – TTE – Holter – Rotablator & OCT.

In addition to be Positioning as consultant, Hazem had Successfully participated as editor in 2020 Egyptian Guide for cardiac rehab and exercise it presented with cardiovascular disease.

Beside devoting to his work as cardiologist.

Prof. **Hazem Khamis** was Head of sports cardiology branch in Egyptian society of cardiology.

Emergency room is the first contact department for critically ill patients where physicians face significant clinical challenges on routine basis.

One of the most important scenarios is the cardiovascular emergencies.

An early diagnosis and appropriate therapy can make a life saving process.

A focused good clinical history and a precise clinical examination is the initial approach.

Various simple investigation and imaging tools like electrocardiogram, chest X-ray, abdominal ultrasound, and echocardiography are considered very useful in the emergency room.

In this modern era of medicine these applications has become an extension of physical examination and can provide timely information to reach diagnosis.

Echo-Doppler study is a diagnostic modality that can provide detailed information about a specific cardiac pathology.

Specifically, it can provide structural, functional and hemodynamic information in a short period of time Additionally, portable machines and hand-held devices have made the procedure more easy and ideal for patient evaluation in the emergency room, coronary care units, intensive care units and the specialized post-operative cardiac surgery care units.

The purpose of this workshop is to provide practical recommendations for efficient use of echocardiography in the emergency room and different intensive care units.

Hence all physicians managing critically ill patients should learn the skill of echocardiographic examination in a focused manner

Prof. Azza Farrag

Professor of Cardiovascular
Medicine at Cairo University

Prof. Azza Farrag is a Professor of Cardiovascular Medicine and Head of the non-invasive cardiovascular unit at Cairo University.

She is a supervisor of the first Professional Diploma in Adult Echocardiography from Cairo University and is the Head of Cardiac Care Unit in Nasr Abary Emergency Hospital.

Prof. Azza is also a Head of Egyptian Echocardiography Working Group of EgSC. H19

Emergency room is the first contact department for critically ill patients where physicians face significant clinical challenges on routine basis.

One of the most important scenarios is the cardiovascular emergencies.

An early diagnosis and appropriate therapy can make a life saving process.

A focused good clinical history and a precise clinical examination is the initial approach.

Various simple investigation and imaging tools like electrocardiogram, chest X-ray, abdominal ultrasound, and echocardiography are considered very useful in the emergency room.

In this modern era of medicine these applications has become an extension of physical examination and can provide timely information to reach diagnosis.

Echo-Doppler study is a diagnostic modality that can provide detailed information about a specific cardiac pathology.

Specifically, it can provide structural, functional and hemodynamic information in a short period of time Additionally, portable machines and hand-held devices have made the procedure more easy and ideal for patient evaluation in the emergency room, coronary care units, intensive care units and the specialized post-operative cardiac surgery care units.

The purpose of this workshop is to provide practical recommendations for efficient use of echocardiography in the emergency room and different intensive care units.

Hence all physicians managing critically ill patients should learn the skill of echocardiographic examination in a focused manner

Dr. Shaymaa Elsayed

Senior Specialist at AlSalam Specialized Hospital

Dr. Shaymaa Abdelmoaoul Elsayed received her bachelors degree in Medicine and Surgery from Ain Shams University. She then proceeded to complete her 4 National Heart Institute, Giza, from 2012 till 2016.

Dr. Shaymaa attained her Msc degree in Cardiology at 2017 from Ain Shams university, and worked as a specialist cardiologist at adult cath lab unit , EPS cath lab unit, Congenital structural cath lab unit, CCU, ER, non-invasive lab of echocardiography, and stress cardiac. She joined Alnkhil hospital cardiology clinic, Manama, Bahrain and moved on to Sh.Khlifa Alyousuf Medical Hospital's cardiology department. She is a member of cardiology club Bahrain, and Bahrain Medical Society. Additional to this, Dr. Shaymaa has attended and participated in many international conferences

Emergency room is the first contact department for critically ill patients where physicians face significant clinical challenges on routine basis.

One of the most important scenarios is the cardiovascular emergencies.

An early diagnosis and appropriate therapy can make a life saving process.

A focused good clinical history and a precise clinical examination is the initial approach.

Various simple investigation and imaging tools like electrocardiogram, chest X-ray, abdominal ultrasound, and echocardiography are considered very useful in the emergency room.

In this modern era of medicine these applications has become an extension of physical examination and can provide timely information to reach diagnosis.

Echo-Doppler study is a diagnostic modality that can provide detailed information about a specific cardiac pathology.

Specifically, it can provide structural, functional and hemodynamic information in a short period of time Additionally, portable machines and hand-held devices have made the procedure more easy and ideal for patient evaluation in the emergency room, coronary care units, intensive care units and the specialized post-operative cardiac surgery care units.

The purpose of this workshop is to provide practical recommendations for efficient use of echocardiography in the emergency room and different intensive care units.

Hence all physicians managing critically ill patients should learn the skill of echocardiographic examination in a focused manner

Prof. Tawfik Khoja

Family and Community Medicine,
General Secretary of the Arab Health Federation
Consultant & Professor of Public Health-Imperial College -London

Prof. **Tawfik Khoja** is a Family and Community Medicine Consultant & Professor of Public Health. He was the Director General of PHC Centers at MOH – KSA, the Executive Board Health Ministerial Council for the Cooperation Council States for more than 16 years, as well as Deputy Chairperson of the Arab Union Anti-Forgery and Counterfeit.

He is now the General Secretary of the Arab Hospital Federation and the Deputy Chairperson of the Arab Union for Governance. He is a member of the Board of the Islamic Organization for Medical Science. Prof. Tawfik holds a Bachelor's degree in medicine and surgery and a Postgraduate diploma in Family Medicine, from King Saud University. He has been a fellow of the Royal College of General Practitioners (RCGP), since 1997 and a fellow of Royal Society (FFPH).

Prof. **Tawfik** also has a fellowship in Medicine (FRCP) and is currently a Professor in Oklahoma University, USA and Imperial College, London, UK. Prof. Tawfik has a long list of publications in many books, manuals, and scientific articles in social, environmental, epidemiological and scientific journals. He won many laurels to his credit and is the founder and a member of more than 30 scientific societies, as well as a consultant to many.

AI in healthcare provision is no longer a distant future. It is stepping into the New Era of Innovation. It is already changing the way health facilities and healthcare providers work and our patient's experience. AI has the potential to improve outcomes, reduce costs and increase patient address each individual. It is fast becoming a staple in provider education and in assessment and diagnosis. And it is increasing the ability of clinicians to provide personalized care, to raise the quality of services development. The impact of AI also on our workforce and training systems is unprecedented and will grow further in the future. The use of AI raises specific ethical challenges when using AI and processing large amounts of data in medical care.

We need to highlight & focus on both the ethics of medical care and the ethics of AI and Data handling. We will continue to develop a better understanding of how to apply these technologies, allowing healthcare providers to be even more inclusive and pragmatic. So, from this prestigious conference, I urge the GCC health administrators to give more attention to the GCC- GCC Guidelines on Ethical & Legal Aspects of Artificial Intelligence Policies and Regulatory Framework.

Also, the Key guidance for all the above is: 1) Develop, deploy, and use AI systems in a way that adheres to the ethical principles of respect for human autonomy, prevention of harm, fairness, and explicability 2) Pay particular attention to situations involving more vulnerable groups such as children, persons with disabilities, and others that have historically been disadvantaged or are at risk of exclusion 3) Acknowledge and address the potential tensions among these principles, including impacts that may be difficult to anticipate, identify or measure.

Lastly, the use of AI for health nevertheless raises transnational ethical, legal, commercial, and social considerations. This ethical framework must be adequately addressed if AI is to be widely used to improve human health, preserve human autonomy, and ensure equitable access to such technologies.

Dr. Boro Dropulic

Executive Director of Caring Cross & CEO of Vector BioMed

Dr. Boro Dropulic received his PhD from the University of Western Australia and his MBA from the Johns Hopkins University. He has been in the gene therapy field since the late 1980s.

After a Fogarty Fellowship at the NIH, he joined the faculty at JHU where he worked on developing Lentiviral vectors as safe, GCG, HIV-based gene therapy. After six years in academia, he founded his first company VIRxSys and led the team that first demonstrated the safety of lentiviral gene therapy in humans. He then founded Vector BioMed, a CDMO company which first developed the Lentiviral vector used to produce Kymriah™, the first FDA-approved gene therapy product.

Dr. Boro has spearheaded the acquisition of Lentigen by Miltenyi Biotec in 2014.

Seeing a need for improved business models to support the affordability and accessibility of gene therapy products, Boro co-founded Caring Cross and serves as the Executive Director.

The current price for a one-time commercial CAR-T cell therapy, not including hospital costs, is at least $300,000 per dose. Such pricing is not sustainable in high-income countries, in the gene therapy space, the current business model can only work if access to these transformative therapies. A centralized model currently used for the manufacture and distribution of commercial CAR-T cells drives up their cost due to the logistical and infrastructure needs of this model. A more cost-effective way is to manufacture the final CAR-T cell product locally at the place-of-care. A recent study, the overall manufacturing cost of a CAR-T cell therapy for B-cell Non-Hodgkin's and Pediatric Leukemia using locally manufactured CAR-T cells produced outstanding clinical outcomes and a cost of goods (COGS) of approximately $15,000 per dose.

Sol Cam, 2020, https://www.nature.com/articles/s41467-021-27212-6)

Caring Cross is collaborating with clinical centers around the world to develop and improve the access of CAR-T and other personalized cellular therapies that are manufactured locally at, or close to, the hospitals treating the patients needing these therapies.

The place-of-care manufacturing significantly reduces the costs of manufacturing CAR-T and other gene-modified cellular products and promises to improve their affordability and access around the world.

Dr. Jean Antoine Ribeil

Clinical Director Sickle Cell Center for Excellence & Associate
Professor in Medicine Boston University School of Medicine

Dr. Jean-Antoine Ribeil is a Clinical hematologist who specializes in Red Cell Disorders. Between 2001 and 2017, Dr. Ribeil was at Necker University Hospital in Paris, where he oversaw the clinical care of adult patients with hemoglobin disorders, as well as directing research notably in the field of gene therapy for hemoglobinopathies, which has enabled him to successfully treat both the first sickle cell and the first beta-thalassemia patient with the Lentiglobin BB305 gene therapy vector.

Between September 2017 to April 2021, Dr. Ribeil worked at bluebird bio in the USA and was the medical director in charge of designing and shepherding the multicenter Lentiglobin gene therapy clinical trials for Sickle Cell Disease.

In May 2021, Dr. Ribeil moved to Boston University Medical Center to become the Clinical Director of the Sickle Cell Disease Center and Associate Professor of Medicine and resumed his academic research and clinical activities in patient-centered clinical work.

Up to now, the only curative treatment for hemoglobinopathies has been hematopoietic stem cell (HSC) allogenic transplant with a matched sibling donor, but most patients don't have access to stemtransplant because they don't have a compatible sibling donor. In the last few years, autologous HSPCs that have been modified ex vivo with a viral vector or with DNA nucleases to obtain erythroblasts expressing HbF or HbAT87Q have been used in SCD or TDT patients with encouraging results. Ex vivo correcting HSPCs with normal hemoglobin genes, their therapeutic potential and reduce complications in sickle cell disease. Hemoglobin A and F-and HbS polymorphism properties.

Hemoglobin F production is a complex process, in which the transcription factor BCl11A plays a key role in silencing γ-globin genes. The types of gene therapy we will mainly discuss include gene addition, and gene editing. Gene therapy is developed initially by mobilizing with Plerixafor and collecting patient CD34+ hematopoietic stem and progenitor cells. Once stem cells are collected and modified to obtain a gene therapy product, patients are treated with chemotherapy to suppress patient hematopoiesis and ensure that the treated stem cell will engraft. Lentiglobin (sickle)gene autotransfer gene therapy product is a suspension of autologous CD34+ cells enriched and transduced with a lentiviral vector encoding hemoglobin HbAT87Q.

The published results with Lentiglobin gene therapy showed that in the Group C of HGB-206 study, all patients had hemoglobin increased from a median value of 8.5g/dL to 11g/dL or more 6 to 36 months after infusion. In 25 patients who were later evaluated, all described a resolution in vaso-occlusive crises. Gene editing, using CRISPR-Cas9 technology,isoagenicgene autotransfer was cell that targets fetal hemoglobin suppressor BCL11A showed HbF expression in a greater proportion of cells. Published interim results of the CLIMB study using CTX001 gene editing showed over 95% persistan hemoglobin F expression. While gene therapy for SCD is not yet approved by health agencies, the patients should receive information about this potential treatment. This would allow for time to prepare patients prior to myeloablative conditioning for gene therapy, insure those with iron overload are adequately chelated and optimize those with organ dysfunction.

Dr. Gaby Moawad

Founder of CEAPS & Clinical Associate
Professor of Obstetrics and Gynecology
The George Washington University School
of Medicine and Health Sciences

Dr. Gaby Moawad is a board-certified gynecological surgeon and the founder of The Center for Endometriosis and Advanced Pelvic Surgery in USA.

Alongside his extensive experience in the field of Gynecology, Dr. Moawad excels in Laparoscopic and robotic hysterectomy.

Being named Top Doctor in Washington DC from the year 2015 to 2023 by the Washingtonian and Castle Connolly is just one of the many accolades.

He has received the AAGL Award for Excellence in Endoscopic Procedures from the American Association of Gynecologic Laparoscopists (AAGL) and has held many of the roles of AAGL Chair of Research Committee and Chair of Robotic Committee and currently serves on the board of directors of the foundation of AAGL.

Dr. Gaby Moawad has earned many grants, most notably a grant from the NIH.

In addition to being a published author of more than 100 peer reviewed publications, he is a recognized national and international speaker.

Technology has been integrated into every face of human life, and whether it is completely advantageous remains unknown, but one thing is for sure, we are dependent on technology Medical advancements have led to the creation of artificial intelligence, machine learning, and augmented realities are widespread and have helped countless patients. The purpose of this talk is to highlight the different technologies currently being utilized in a variety of surgical specialties.



Dr. Mariam Matar

Founder & chairman
Sheikh Zayed Genetics Research

Physician. Scientist. Healthcare Influencer.

Leadership Mentor

- A leading healthcare influencer, pioneered study of genes and advocates public education and awareness of genetic disorders across the ME region. A true game changer in the field of genetic research and biotechnology in the Arab world, she is single handedly responsible for putting UAE on the global map of genetic research and innovation. As the pioneer genetic scientist, she played a lead role in bringing new legislations for pre-marital screening, preventive genetic testing, and relevant mandatory legislations at the government level in the UAE.
- MBBS and PhD in the genetic and epigenetics filed.



Dr. Fatema Marhoon

Medical Doctor at the National Genome Center & Genetic Counselor

Dr.Fatema Marhoon is a Medical Doctor at the National Genome Center & Genetic Counselor.
Dr.Fatema Marhoon graduated from the Arabian Gulf University, and is a pioneer young physician in genetics, an advocate and public awareness speaker.
Dr. Marhoon is the first Bahraini MD to graduate from Genetic Counseling program in Oman (2020). In 2023 June, She completed her advanced professional training in Harvard Medical School (BWH) for Variant Analysis, NGS and clinical genetics. She is also expecting her MSc in Personalized Medicine in November, 2023.
Her current fields of research and publication includes Nuerodiversity in genetics, pharmacogenetics, epigenetic factors and rare diseases ethics, equity and accessibility.

Genome mapping is a powerful tool that enhances genetic testing capacity and establish a detailed understanding of the genetic makeup of the Bahraini population, enabling the healthcare providers, policymakers, and researchers to make data-driven decisions regarding disease prevention, diagnosis, and treatment strategies.
This knowledge helps optimize resource allocation, personalize healthcare interventions, and develop targeted public health initiatives.
Whole Genome Sequencing (WGS) applications derived from genome mapping have substantial effects on both individuals and the population. As this technology allows for the identification of genetic variants associated with disease susceptibility, drug response, and treatment outcomes. Moreover, the integration of precision medicine and genomic medicine relies on the insights gained from genome mapping. Precision medicine, which aims to deliver personalized treatments based on an individual's genetic profile, can be enhanced through the comprehensive genomic data obtained from genome mapping. This integration enables healthcare providers to match patients with the most effective therapies, optimize drug dosages, and minimize adverse drug reactions.
In fact, the future of genomic results lies in the application of Artificial Intelligence (AI).
By leveraging AI, healthcare systems can harness the power of genome mapping results to enhance disease risk prediction, identify potential therapeutic targets, and develop innovative treatment strategies.
In conclusion, genome mapping in the Bahraini population holds significant importance for healthcare design, as it facilitates informed decision-making and enables tailored interventions. With WGS applications, precision medicine integration, and the utilization of AI, the potential for genome mapping to revolutionize healthcare delivery and improve health outcomes in Bahrain is substantial.



Dr. Nooraldaem Yousif

Consultant Invasive Cardiologist & Deputy Head of the Cath Department
Mohammed bin Khalifa Specialist Cardiac Centre (MKCC)

Dr. Nooraldaem Yousif is a Consultant Interventional Cardiologist and Deputy Head of Cardiac Catheterization Laboratories at Mohammed Bin Khalifa Specialist Cardiac Centre.
He also holds a Swiss Fellowship in Interventional Cardiology from Andreas greuntzg Catheterization Laboratorires.

Since Gruntzig introduced a simple balloon angioplasty technique, percutaneous coronary intervention has undergone extraordinary growth and has now surpassed bypass surgery in frequency of performance.
Several critical breakthrough technologies account for this remarkable progress: intracoronary stents have increased success rates and reduced restenosis; adjunctive antiplatelet therapy and intravascular imaging has reduced periprocedural complications. Furthermore, drug-eluting stents coated with cell-cycle inhibitors have shown great promise for further reducing restenosis, possibly to negligible levels.



Dr. Zubaida Alshaikh

Medical Consultant &
Chief, Health Profession
Regulation Department - NHRA

Dr.Zubaida Alshaikh is a Consultant Family Physician & Chief of Health Professions Regulations department at NHRA.

Dr.Zubaida Alshaikh holds a Bachelors of Medicine & Surgery and successfully completed Bahrain's Family Physicians Residency Program.
Prior to joining NHRA in 2015,she worked at the Ministry of Interior as the in-charge doctor for women in jail and at the Ministry of Health as a Primary Care Family Physician .

Dr.Zubaida Alshaikh is now the Head of the Educational Certificates Evaluation Committee, the Deputy Head of the Medical Disciplinary Commitee and Medical Advisory Committee as well as an active member of the national committee for IVF.

The lecture will describe and explain the regulations of aesthetic medicine in Bahrain. It will briefly go over the different types of aesthetic procedures and clarify their limitations.



Col. Dr. Adel Khalifa

Consultant Cardiologist, Interventional Cardiac Electrophysiologist &
Head of electrophysiology department, cardiac pacing and tachyarrhythmia devices at
Mohammed Bin Khalifa Bin Salman AlKhalifa Cardiac Centre (MKCC)

Col. Dr. Adel is a Consultant cardiologist at Moammed bin Khalifa Al Khalifa Cardiac centre and Bahrain's first interventional cardiac electrophysiologist.
He is board certified in internal medicine and adult cardiology from University of Toronto, Canada.
Subsequently he did a sub-speciality clinical fellowship in cardiac electrophysiology at Toronto General Hospital.
During his cardiology residency and clinical fellowship years he did research focusing on the "Spatial organization of ventricular fibrillation in explanted Langendorff human heart" which he presented in the annual Ursula Bangs Clinical and Research Day at University of Toronto.
Subsequently he presented his research poster at the Canadian Cardiovascular Society Meeting in Montreal/Canada in 2015. After returning from Canada, he established the country's first electrophysiology (EP) laboratory in 2010, subsequently established an advanced EP program utilizing 3D mapping system in 2012 and established a program for cryoablation of atrial fibrillation in 2016.
He is a founding board member of the Gulf Heart Rhythm Society (GHRS).
He is a Fellow of the Royal College of Physicians of Canada, and Fellow of the Gulf Heart Association.
He is a speaker in local, regional and international conferences.
His research interests include atrial fibrillation, new oral anticoagulants, implantable cardiac devices, heart failure, sudden cardiac death and sports cardiology.

Dyslipidemia, characterized by abnormal lipid levels in the blood, is a prevalent and significant risk factor for cardiovascular disease.
This presentation aims to provide a comprehensive overview of dyslipidemia management, risk factors associated with dyslipidemia, exploring its impact on cardiovascular health, reviewing current guidelines and recommendations for management, discussing lifestyle modifications and pharmacological interventions, and analyzing long-term outcomes. The presentation covers various aspects of dyslipidemia management, including the different types of dyslipidemia, their role in the development of atherosclerosis and coronary artery disease, and the importance of risk assessment tools in guiding treatment decisions. It delves into the efficacy, safety, and potential side effects of lipid-lowering medications, as well as the concept of combination therapy and the emerging therapies available.
By presenting a comprehensive overview, this session aims to equip healthcare professionals with the knowledge and tools necessary for effective dyslipidemia management, ultimately reducing the burden of cardiovascular disease and improving patient outcomes.



Dr. Karolina Kobus

Head of Genomics and Precision Medicine
Department & Innovation and Technology Advisor at ExpressMed
Diagnostics & Research

Dr. Karolina is molecular geneticist with more than 14 year sof experience in the field of reproductive genetics, prenatal testing, oncogenetics and precision medicine.
Dr. Kobus has been creating many awareness and preventative strategies.
She previously worked at the Max Planck Institute for Molecular Genetics, the Human Genetics Department at Charite University hospital, Germany and the National Genetics Center at the Ministry of Health, Oman. She is currently the Head of Genomics and Precision Medicine Department & Innovation and Technology Advisor at ExpressMed Diagnostics & Research.

Genetic testing can play an important role in the diagnosis and management of cardiovascular conditions. It can help diagnose inherited cardiovascular conditions by identifying genetic mutations associated with increased risk of sudden cardiac death, genetic causes of cardiomyopathies, inherited thrombophilia, Marfan syndrome, Brugada syndrome, genetic causes of hypertension and genetic causes of heart failure. This information can help guide preventive measures, treatment decisions and lifestyle changes.

Genetic testing can also provide important information for family members who may also be at risk so that preventive measures can be implemented. By identifying genetic causes of cardiovascular conditions, genetic testing can help cardiologists to personalize the diagnosis, management and treatment of their patients.

Recently, the American Heart Association (AHA) issued a statement recommending genetic testing for patients diagnosed with all forms of cardiomyopathy. In addition, the American College of Cardiology (ACC) and European Society of Cardiology (ESC) recommended genetic testing for individuals with a personal or family history of sudden cardiac death, or for individuals with a personal or family history of certain inherited arrhythmias such as long QT syndrome.



Dr. Mariam Baqi

Consultant Dermatologist & Founder and Medical Director of Nadhara Skin Center

Dr. Mariam Baqi Consultant Dermatologist & Founder and Medical Director of Nadhara Skin Center.

Dr. Mariam Baqi is Arab board certified in Dermatology with a Double fellowship certificate from Mount Sinai New York in psoriasis and non surgical comsetic dermatology. She was a the Head of training Head in the dermatology unit of Salmaniya Medical Complex, Ministry of Health.
Dr. Mariam Baqi is a public figure and has participated in many international and regional events.

Anatomy is the constant non variable landmark any physician should rely on, all other features may change and differ over ethnicity and rational backgrounds.
Learning the pearls in practice will help the physician to build a tailored plan for each patient and end up with more efficient plans that save time with less side effects.



Prof. Sattam Saud Lingawi

Professor of Neuroradiology at King Abdulaziz University

Prof. Sattam Saud Lingawi holds a Bachelors of Medicine & Surgery from King Abdulaziz University, Canadian Fellowships in Radiology and Neuroradiology as well as American Boards in Diagnostic Radiology and Neuroradiology.
Prof. Sattam Saud Lingawi held several positions in different universities in the Kingdom of Saudi Arabia like King Abdulaziz University, King Saud bin Abdulaziz University for Health Sciences and Other Saudi Universities.
He was a member in the Shura Council: (2013 - 2017) and Member of the Parliamentary Committee in the Shura Council Representation of the Kingdom within the delegation of the Shura Council to multiple countries.
Prof. Sattam Saud Lingawi is an author of 4 medical textbooks in neuroimaging and has published multiple articles in peer-reviewed journals .
Additional to this,
Prof. Sattam Saud Lingawi is an accredited scientific reviewer in local and international journals.

Artificial intelligence (AI) has emerged as a transformative technology in medical imaging, enabling the development of new tools for diagnosing diseases, monitoring treatment response, and improving patient outcomes.
In this review, we summarize recent advances in AI for medical imaging and highlight key applications across different medical specialties. We also discuss challenges & opportunities for future research and clinical translation.
One of the most promising areas of AI in medical imaging is in the detection and classification of tumors. Deep learning algorithms have been developed to accurately identify and localize lesions in medical images, such as mammograms and lung CT scans, with high sensitivity and specificity.
These algorithms can help radiologists detect cancer at an earlier stage, when it is more treatable, and reduce the number of false-positive results, which can lead to unnecessary biopsies and anxiety for patients.
AI can also be used to predict the likelihood of disease recurrence or treatment response based on imaging features. For example, a recent study used a machine learning model to predict which patients with glioblastoma, a type of brain cancer, were most likely to benefit from a certain type of chemotherapy based on MRI scans. This type of personalized medicine approach could improve treatment outcomes and reduce healthcare costs.
Despite these promising applications, there are several challenges to the widespread adoption of AI in medical imaging.
One major challenge is the need for large amounts of annotated data to train deep learning algorithms, which can be time-consuming and costly to acquire. Additionally, there are concerns about the interpretability and transparency of AI algorithms, which can make it difficult to understand how decisions are being made and to ensure that biases are not introduced.
In conclusion, AI has the potential to revolutionize medical imaging and improve patient outcomes across a wide range of medical specialties. While there are challenges to overcome, continued research and development in this field could lead to significant improvements in disease detection, treatment, and prevention.



Prof. Maiy Hamdy El Sayed

Professor and Head of the Cardiology
Department at Ain Shams University

Prof. Maiy H. El Sayed is a Professor and Head of the Cardiology Department at Ain Shams University.

Prof. Maiy H. El Sayed graduated from Ain Shams University medical school in December 1982, and attained a Masters degree in Cardiology in 1986. She trained as a pediatric and congenital cardiologist at the Royal Brompton Hospital - UK .
Prof. Maiy H. El Sayed founded the congenital and structural heart disease Unit at Ain Shams university which was the first specialized unit in pediatric and adult congenital cardiac interventions in Egypt.
Prof. Maiy H. El Sayed is now the Director of the Egyptian fellowship program of congenital heart disease and Pediatric Cardiology , the President of the Egyptian working group of Pediatric cardiologists, the Secretary general of the Pan Arab Congenital Heart disease Association [PACHDA] , a Member of the European Society of Cardiology, and a Fellow of PICS CPC member of the ESC annual meeting.

The presentation will include current updates in diagnosis and management of congenital heart disease including recent guidelines and recent methods of diagnosis and treatment especially transcatheter based procedures





Dr. Jassim Haji

President of International Artificial Intelligence Group & Executive Advisor at HH Sh. Nasser Artificial Intelligence Research & Development Centre.

Dr. Jassim Haji is an international expert, strategist, and researcher in Artificial Intelligence and Digital Transformation.
He is currently President of Artificial Intelligence Group and Executive Adv .
At HH Sh Nasser Al Research & Development Centre.
He participated as a key speaker and chairman in over 365 technology conferences in the Middle East and Europe to cover the latest technologies such as Artificial Intelligence, Cloud Computing, Big Data, Cyber Security, and Digital Transformation
He also published articles in relation to the above topics.
Dr. Jassim Haji managed to achieve forty-three top Middle Eastern technology, innovation, and entrepreneurship awards, including 12 Chief of Information Technology distinguished awards.
Furthermore, he has been featured on the cover page of 19 international technology and aviation magazines with over 180 interviews. Moreover, published five books in English, Spanish, and Arabic on Artificial Intelligence, Algorithms, Digital Transformation post-COVID-19, and Technology and over 720 articles on AI & technologies with international land international press and media in English and Arabic.
Concept of AI - History of AI - Data, Algorithms and Computing - Generative AI - AI in Healthcare Applications - Ethics - Future of Jobs



Dr. Ahmed Naga

Head of Clinical Pathology Department, ExpressMed Diagnostics & Research

Dr. Ahmed is a medical doctor holding a master degree in clinical pathology with more than 10 years of experience in laboratory management and clinical pathology.
He is the Head of the Clinical Pathology Department at ExpressMed Diagnostics & Research and holds an M.B.B.Ch. and MSc Clinical Pathology.
Dr. Ahmed trained in National Cancer Institute, Cairo, Egypt and is a Certified Professional in Healthcare Quality.

Cardiovascular diseases (CVD) are the leading causes of mortality and morbidity in the world. Biomarkers detection is used as a non-invasive method for the diagnosis and prognosis of the CVD. Metabolomics is one of the newest omics sciences that allow us to understand the cardiac metabolism and detect any abnormal changes that may explain the molecular pathology of CVD.
LC MS/MS is used to detect hundreds of metabolites precisely from any biological samples.



Dr. Samer Ellahham

Senior Cardiovascular Consultant & Director of Accreditation in the Quality and Safety Institute in Cleveland Clinic Abu Dhabi

Dr. Samer Ellahham is a Senior Cardiovascular Consultant & Director of Accreditation in the Quality and Safety Institute in Cleveland Clinic Abu Dhabi.

Dr. Samer Ellahham is American Board Certified in Internal Medicine, Cardiovascular Disease, Vascular Medicine, and American Board of Medical Quality.
He is a Certified Professional in Healthcare Quality (CPHQ) by The National Association for Healthcare Quality (NAHQ), certified in Medical Quality (CMQ) by The American Board of Medical Quality (ABMQ), certified as DEEP Model assessor and Lead Trainer in TeamSTEPPS.

Dr. Samer Ellahham is an avid researcher; his research includes cardiology, artificial intelligence, telehealth, blockchain, metaverse, lean-six sigma and patient safety.
He is a recognized world-leader in these fields.

Medical errors are recognized as major threats to patient safety worldwide.
Lack of streamlined communication and an inability to share and exchange data are among the contributory factors affecting patient safety.
To address these challenges, blockchain can be utilized to ensure a secure, transparent and decentralized data exchange among stakeholders. In this presentation, we discuss six use cases that can benefit from blockchain to gain operational effectiveness and efficiency in the patient safety context. The role of stakeholders, system requirements, opportunities and challenges are discussed in each use case in detail. Connecting stakeholders and data in complex healthcare systems, blockchain has the potential to provide an accountable and collaborative milieu for the delivery of safe care. By reviewing the potential of blockchain in six use cases, we suggest that blockchain provides several benefits, such as an immutable and transparent structure and decentralized architecture, which may help transform health care and enhance patient safety. While blockchain offers remarkable opportunities, it also presents open challenges in the form of trust, privacy, scalability and governance. Future research may benefit from including additional use cases and developing smart contracts to present a more comprehensive view on potential contributions and challenges to explore the feasibility of blockchain-based solutions in the patient safety context.



Dr. Nedhal Khalifa

Consultant Dermatologist & Founder and Medical Director of DermaOne Center

Dr. Nedhal Khalifa is a Consultant Dermatologist & Founder of Derma One Medical Centre.
She holds a Bachelors Degree from the Arabian Gulf University, and a Masters and PhD from King's College London.
Dr. Nedhal is a member of the European Academy of Dermatology & Venereology.
She is also a member of various boards in the field of dermatology & aesthetics and her 20+ years of experience in the field of dermatology and aesthetic medicine have equipped her to become a frequent speaker at various international conferences.

Lasers & Energy based devices are popular treatments for skin rejuvenation and resurfacing.
The talk will discuss the various technologies available, as well as, the latest updates in the market with emphasis on scar treatment and hyperpigmentation



Prof. Dominique Charron

Professor of Immunology at Université de Paris

Prof. Dominique Charron is a Professor Emeritus of Medicine at Paris University. Medical Advisor for international biology at the international affairs department of the Greater Paris University Hospital (AP-HP) General Directorate.
He was appointed in 2016 Consulting Professor at Jiaotong University/Ruijing Hospital in Shanghai & Professor at Unistra (University of Strasbourg-France).He is an SAB member of the Chinese society of Blood Transfusion since 2013 and is the Editor in Chief of the international journal "Exploration of Immunology". Prof. Charron is the founding President of HLA-MED (HLA & Medecine) and he is the co Founder and CMO of Asfalia Biologics.

Displaying the highest degree of allelic polymorphism of any functional and medically relevant system (more than 30000 alleles) the HLA complex is a landmark and a model of personalized predictive and preventive medicine.
I will illustrate the impact and future potential of HLA NGS genetic typing in organ and hematopoietic transplantation .Also i will emphasize the importance of HLA in Cancer & Infectious diseases.Other Immunogenes such as TcR,Cytokines and Receptors contribute to the fine tuning of individual immune responses to pathogens,cancer but also drugs qualifying the HLA genes as genuine pharmacogenes.
The role of immunogenomics is fast developing and the DNA sequencing highthroughput technologies are now allowing to unravel the potential usefulness of HLA,TcR,Cytokine & receptor polymorphisms in personalized medicine and public health .



Dr. Mariam Matar

Founder & chairman
Sheikh Zayed Genetics Research

Physician. Scientist. Healthcare Influencer.

Leadership Mentor

- A leading healthcare influencer, pioneered study of genes and advocates public education and awareness of genetic disorders across the ME region. A true game changer in the field of genetic research and biotechnology in the Arab world. she is single handedly responsible for putting UAE on the global map of genetic research and innovation.
As the pioneer genetic scientist, she played a lead role in bringing new legislations for pre-marital screening, preventive genetic testing, and relevant mandatory legislations at the government level in the UAE.
- MBBS and PhD in the genetic and epigenetics filed.



MKCC

Mohammed Bin Khalifa Bin Salman Al Khalifa Specialist Cardiac Centre (MKCC) was established, and services were commenced from 1st October 1992 to provide tertiary cardiac care for the population of Bahrain. In the past 29 years since its inception, the Centre has progressed rapidly in the patient volume and modalities of care.
MKCC continuously aims to improve and uphold its commitment to offer the highest quality of healthcare in the most efficient manner. The Cardiac Centre was awarded four years of accreditation from the Australian Council on Healthcare Standards International (ACHSI) from the year 2013 to 2017.
MKCC has a distinctive vision to be the leading National and international centre for the diagnosis, treatment and care of patients with heart disease, creating and disseminating knowledge through research and education. It holds a vast range of highly qualified cardiac professionals who bring years of experience and skills to the public, showcasing a wide scale of expertise across cardiology



Adara Center

ADARA Center is the first internationally-renowned beauty & wellness training center in Bahrain. The center is affiliated with the world-renowned CIDESCO organization in Switzerland and the distinguished beauty school IS'ADY in Francewhich serves as their inspiration and benchmark to guide and train their students. T
he distinctive curriculums provided by ADARA equip students with the skills necessary to help them make their mark in today's beauty & wellness industry through a carefully planned combination of theoretical knowledge and practical, hands-on training.